If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...
In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE). The US regulator has cleared Eohilia ...
(Yicai) Dec. 31 -- Shares of Everest Medicines dropped after the Chinese biopharmaceutical company's immunoglobulin A ...
SaveHealth reports seven asthma medication categories, including inhaled corticosteroids and biologics, helping manage ...
Please provide your email address to receive an email when new articles are posted on . Patients had mild asthma and uncontrolled symptoms. Doses included an albuterol-budesonide combination or ...
Hosted on MSN
Budesonide-Formoterol More Effective Than Salbutamol for Preventing Asthma Attacks in Children
WEDNESDAY, Oct. 8, 2025 (HealthDay News) -- In children aged 5 to 15 years with mild asthma, budesonide-formoterol reliever monotherapy is superior to salbutamol for preventing asthma attacks, ...
Inhalers that combine providing immediate relief with a longer-term preventative effect are already recommended as the standard treatment for mild asthma among people aged 12 and above in the UK, US ...
As with other drugs, Tarpeyo (budesonide) can cause side effects, such as swelling of the hands, legs, ankles, or feet and high blood pressure. If these side effects become difficult to tolerate, talk ...
Severe exacerbation occurred in 5.1% of patients taking albuterol/budesonide compared with 9.1% of patients taking albuterol alone in the on-treatment efficacy population. Albuterol/budesonide ...
The measles outbreak in West Texas has reignited familiar anti-vaccine tactics: claiming there are readily available treatments for the disease while sowing doubt in the safety of vaccines. Health and ...
Daniel Payne reports on how the health industry and Washington influence and impact each other. He joined STAT in 2025 after covering health care at POLITICO. You can reach Daniel on Signal at danielp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback